{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T02:50:38Z","timestamp":1780973438602,"version":"3.54.1"},"reference-count":22,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,8,1]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:p>A woman in her mid-60s presented to the hospital due to a history of nausea, vomiting, shortness of breath, dyspnoea on exertion and polyuria. She was receiving medical therapy for advanced non-small cell lung cancer and recently initiated immune checkpoint inhibitor (ICI) immunotherapy. Investigations revealed lab results consistent with diabetic ketoacidosis (DKA), elevated cardiac biomarkers, multiple cardiac arrhythmias and reduced ejection fraction on transthoracic echocardiogram. Cardiac catheterisation showed non-obstructive coronary arteries.<\/jats:p>\n               <jats:p>The patient was diagnosed with an ICI-associated myocarditis and type I diabetes due to recent initiation of the ICI durvalumab. She was treated with the institutional DKA protocol and received corticosteroid therapy for drug toxicity according to guidelines. She was discharged with marked improvement in symptoms. The patient had good recovery after discharge with further investigations showing improvement in her cardiac ejection fraction on cardiac MRI. She remains on medical therapy with an insulin regimen for diabetes management.<\/jats:p>","DOI":"10.1136\/bcr-2023-255698","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T13:15:36Z","timestamp":1692191736000},"page":"e255698","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Immune checkpoint inhibitor-associated myocarditis and fulminant type I diabetes in a patient with metastatic non-small cell lung cancer"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1862-1636","authenticated-orcid":false,"given":"Brandon Matthew","family":"Davis","sequence":"first","affiliation":[{"name":"Medicine, Augusta University Medical College of Georgia, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Fordjour","sequence":"additional","affiliation":[{"name":"Medicine, Augusta University Medical College of Georgia, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9371-0252","authenticated-orcid":false,"given":"Michael","family":"Chahin","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Augusta University Medical College of Georgia, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avirup","family":"Guha","sequence":"additional","affiliation":[{"name":"Cardiology, Augusta University Medical College of Georgia, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"2025082700135418000_16.8.e255698.1","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/ijc.32960","article-title":"Association between myocarditis and other immune-related adverse events secondary to immune checkpoint inhibitor use","volume":"147","author":"Guha","year":"2020","journal-title":"Int J Cancer"},{"key":"2025082700135418000_16.8.e255698.2","doi-asserted-by":"crossref","DOI":"10.1186\/s13256-021-02858-7","article-title":"Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report","volume":"15","author":"Cham","year":"2021","journal-title":"J Med Case Rep"},{"key":"2025082700135418000_16.8.e255698.3","doi-asserted-by":"crossref","unstructured":"Patel S , Chin V , Greenfield JR . Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism. Endocrinol Diabetes Metab Case Rep 2019;2019. doi:10.1530\/EDM-19-0098","DOI":"10.1530\/EDM-19-0098"},{"key":"2025082700135418000_16.8.e255698.4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025082700135418000_16.8.e255698.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"2025082700135418000_16.8.e255698.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025082700135418000_16.8.e255698.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100265"},{"key":"2025082700135418000_16.8.e255698.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00259-5"},{"key":"2025082700135418000_16.8.e255698.9","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"2025082700135418000_16.8.e255698.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937"},{"key":"2025082700135418000_16.8.e255698.11","doi-asserted-by":"publisher","DOI":"10.1200\/Jco.21.01497"},{"issue":"Suppl 1","key":"2025082700135418000_16.8.e255698.12","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD\u20101 and PD\u2010L1 inhibitors in non\u2010small cell lung cancer: a meta\u2010analysis","volume":"6","author":"Hu","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"2025082700135418000_16.8.e255698.13","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1471-P"},{"key":"2025082700135418000_16.8.e255698.14","first-page":"49","article-title":"Management of acute pancreatitis associated with checkpoint inhibitors","volume":"11","author":"Rogers","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"2025082700135418000_16.8.e255698.15","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw260","article-title":"Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab + ipilimumab","volume":"109","author":"Friedman","year":"2017","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2025082700135418000_16.8.e255698.16","article-title":"Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment","volume":"2019","author":"Meng\u00edbar","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2025082700135418000_16.8.e255698.17","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14050"},{"key":"2025082700135418000_16.8.e255698.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-88307-3","article-title":"Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors","volume":"11","author":"Michailidou","year":"2021","journal-title":"Sci Rep"},{"key":"2025082700135418000_16.8.e255698.19","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"2025082700135418000_16.8.e255698.20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0618"},{"key":"2025082700135418000_16.8.e255698.21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"key":"2025082700135418000_16.8.e255698.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-255698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:14:07Z","timestamp":1756278847000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-255698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,16]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/bcr-2023-255698"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-255698","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}